Sweden's Boule Diagnostics Q2 sales fall on logistics disruptions
Sweden's Boule Diagnostics Q2 sales fall on logistics disruptions
Overview
Sweden diagnostics and OEM reagents provider's Q2 net sales fell 13% yr/yr on currency, demand weakness
Adjusted EPS for Q2 was negative, with net loss reported for the period
Gross margin improved to 40.9% from 38.7% due to higher OEM and reagent sales
Outlook
Company expects instrument procurements and lower distributor inventories to support H2 sales
Boule Diagnostics sees recovering OEM sales and improved gross margin supporting future results
Company expects continued focus on cost savings and working capital management
Result Drivers
CURRENCY HEADWINDS - Negative currency effects reduced Q2 sales by 8%, compounding organic sales decline
GEOPOLITICAL AND LOGISTICS DISRUPTIONS - Lower order intake driven by Middle East tensions, shipping disruptions in the Straits of Hormuz, and limited USD access for key customers
INSTRUMENT SALES DECLINE - Number of instruments sold fell 41%, contributing to lower revenue
Company press release: ID:nMFN8lmSh0
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Miss | SEK 112.20 mln | SEK 115 mln (1 Analyst) |
Q2 Adjusted EPS |
| -SEK 0.04 |
|
Q2 Net Income |
| -SEK 1.70 mln |
|
Q2 Gross Margin |
| 40.90% |
|
Q2 Adjusted Free Cash Flow |
| -SEK 2.40 mln |
|
Q2 Adjusted Operating Income |
| SEK 3.30 mln |
|
Q2 Gross Profit |
| SEK 45.90 mln |
|
Q2 Operating Income |
| SEK 400,000 |
|
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)